Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 573 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in... August 19, 2025 Opinion: What should the cancer agenda look like for the new... September 22, 2022 To My Fellow Nurses May 13, 2021 Get to Know CaringBridge June 3, 2021 Load more HOT NEWS Drug Combination Shows Promise for Rhabdomyosarcoma, but Can It Get to... Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC... Immunotherapy’s Skin Side Effects: Are Microbes to Blame? Having Cancer as a Young Adult Put Me on a Path...
